Generalized Epilepsy Clinical Trial
Official title:
An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less Than 50 kg), in Children (≥ 4 Years Old), Adolescents and Adults Suffering From Primary Generalized Seizures
An open-label, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV), in children (≥ 4 years old), adolescents and adults suffering from primary generalized seizures.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04965571 -
Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
|
||
Completed |
NCT01311440 -
Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy
|
N/A | |
Terminated |
NCT03955432 -
Long-term Cardiac Monitoring in Epilepsy
|
N/A | |
Recruiting |
NCT06425159 -
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
|
Phase 2/Phase 3 | |
Completed |
NCT00150735 -
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
|
Phase 3 | |
Recruiting |
NCT03457961 -
Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
|
||
Withdrawn |
NCT03368469 -
Transcranial Direct Current Stimulation (tDCS) in Children and Adolescents With Epilepsy and Depression
|
N/A | |
Completed |
NCT03590197 -
Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy
|
Phase 4 | |
Completed |
NCT00001325 -
Metabolic Abnormalities in Children With Epilepsy
|
N/A |